About Adastra
Adastra Pharmaceuticals Inc. is a private clinical-stage oncology company committed to providing responsible solutions to advance patient care in oncology. The Adastra lead clinical candidate, zotiraciclib, is initially being developed for the treatment of glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG), two brain cancers characterized by Myc overexpression. Zotiraciclib is the subject of separate clinical studies in GBM, as well as an upcoming pilot study in DIPG.
The Adastra development programs are guided by world-class executives, key opinion leaders and advisors. The core management team has successfully transitioned its years of experience developing oncology drugs in large pharmaceutical companies into the entrepreneurial biotech environment. Adastra is backed by a syndicate of premier life sciences investors, including: Domain Associates, Lee’s Pharma, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest.
Development
Zotiraciclib Mechanism
Zotiraciclib potently inhibits cyclin-dependent kinase 9 leading to apoptotic effect and modulation of the cell cycle. Zotiraciclib blocks the activity of RNA polymerase II, leading to depletion of the key cancer cell survival protein, c-Myc. In glioblastoma cell lines and in vivo models, zotiraciclib has demonstrated broad anti-tumor activity.
Glioblastoma
Overexpression of the Myc oncogene has been reported in >80% of glioblastomas. In vitro and in vivo glioma models have demonstrated that inhibition of Myc reduced proliferation and increased apoptosis.
Two zotiraciclib clinical trials are ongoing in glioblastoma.
Link: NCT02942264
Link: NCT03224104
Hepatocellular Carcinoma
Overexpression of the Myc oncogene has been reported in 40-60% of hepatocellular tumors and is associated with poor prognosis in this patient population.
A zotiraciclib clinical trial in hepatocellular carcinoma will initiate in 1Q 2018 in Hong Kong.
Data
Information on preclinical and clinical data.
- All
- Preclinical
- Clinical
Our Team
Scott Megaffin
Chief Executive Officer
Tracy Lawhon
Chief Operating Officer
Lynne Rollins
Chief Financial Officer
Stuart Gallant
Head, Pharmaceutical Manufacturing
Rosemary Mazanet
Strategic Advisor
Kristan Meetze
Head, Tumor Biology
Jillian Chapas-Reed, MS
Vice President, Clinical OperationsBoard of Directors
Mauro Bove
Lee’s Pharmaceutical Holdings Inc.Ralph E. (Chris) Christoffersen
Partner, Morgenthaler Ventures
Thomas M. Estok
President and Chief Executive Officer, Dracen PharmaceuticalsScott Megaffin
Chief Executive Officer, Adastra Pharmaceuticals
Dennis G. Podlesak
Partner, Domain AssociatesAlain Schreiber
Managing Partner, ProQuest InvestmentsEckard Weber
Partner, Domain AssociatesGrigory Borisenko, PhD
Investment Director, RMIContact
12481 High Bluff Drive
Suite 150
San Diego, CA 92130
202 Carnegie Center
Suite 104
Princeton, NJ 08540
Telephone: (760) 208-6900